Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model

Experimental Hematology

Volumn 43, Issue 2, 2015, Pages 79-88.e4

  Nakauchi, Yusuke ^a   Yamazaki, Satoshi ^a   Napier, Stephanie C ^a   Usui, Jo ichi ^b   Ota, Yasunori ^a   Takahashi, Satoshi ^a   Watanabe, Nobukazu ^a   Nakauchi, Hiromitsu ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE SPECIFIC HLA MONOCLONAL ANTIBODY; HLA ANTIBODY; UNCLASSIFIED DRUG; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; MONOCLONAL ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD DONOR; CELL SURVIVAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ACUTE DISEASE; ALLELE; ANIMAL; CYTOLOGY; DISEASE MODEL; GENE EXPRESSION; GENETICS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; IMMUNOTHERAPY; MONONUCLEAR CELL; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; TRANSGENIC MOUSE; TRANSPLANTATION; XENOGRAFT;

MUS;

ACUTE DISEASE; ALLELES; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 84924986025     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.10.008     Document Type: Article

References (37)

1. Storb R. Edward Donnall Thomas (1920-2012). Nature 2012, 491:334.
2. Ferrara J.L.M., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
3. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300:1068-1073.
4. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
5. Storb R., Gyurkocza B., Storer B.E., et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013, 31:1530-1538.
6. Warren E.H., Deeg H.J. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens 2013, 81:183-193.
7. Martin P.J., Rizzo J.D., Wingard J.R., et al. First- and second-line systemic treatment of acute graft-versus-host disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012, 18:1150-1163.
8. Jørgensen K.A., Koefoed-Nielsen P.B., Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol 2003, 57:93-98.
9. Ikuya Tsuge S.K. Comparison of antibody specificities of four anti-thymocyte/anti-lymphocyte globulin products. Curr Ther Res 1995, 56:671-677.
10. Mueller T.F. Mechanisms of action of thymoglobulin. Transplantation 2007, 84:S5-S10.
11. Knop S., Hebart H., Gratwohl A., et al. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: A randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia 2007, 21:1830-1833.
12. Martínez C., Solano C., Ferrá C., Sampol A., Valcárcel D., Pérez-Simón J.A. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: Results of a phase II study. Biol Blood Marrow Transplant 2009, 15:639-642.
13. Kanda Y., Oshima K., Kako S., et al. Invivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation. Am J Hematol 2013, 88:294-300.
14. Watanabe N., Takahashi S., Ishige M., et al. Recipient-derived cells after cord blood transplantation: Dynamics elucidated by multicolor FACS, reflecting graft failure and relapse. Biol Blood Marrow Transplant 2008, 14:693-701.
15. Yamazaki S., Suzuki N., Saito T., et al. A rapid and efficient strategy to generate allele-specific anti-HLA monoclonal antibodies. J Immunol Methods 2009, 343:56-60.
16. Karaki S., Kariyone A., Kato N., Kano K., Iwakura Y., Takiguchi M. HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies. Immunogenetics 1993, 37:139-142.
17. Ito R., Katano I., Kawai K., et al. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 2009, 87:1654-1658.
18. Nishimori H., Maeda Y., Teshima T., et al. Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. Blood 2012, 119:285-295.
19. Nervi B., Rettig M.P., Ritchey J.K., et al. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp Hematol 2007, 35:1823-1838.
20. Anderson B.E., McNiff J., Yan J., et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003, 112:101-108.
21. Visser J.W., Bauman J.G., Mulder A.H., Eliason J.F., de Leeuw A.M. Isolation of murine pluripotent hemopoietic stem cells. J Exp Med 1984, 159:1576-1590.
22. Sabir H.J., Nehlin J.O., Qanie D., et al. Separate developmental programs for HLA-A and -B cell surface expression during differentiation from embryonic stem cells to lymphocytes, adipocytes and osteoblasts. PLoS One 2013, 8:e54366.
23. Hod E., Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008, 142:348-360.
24. Takanashi M., Atsuta Y., Fujiwara K., et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010, 116:2839-2846.
25. Shaz B.H., Stowell S.R., Hillyer C.D. Transfusion-related acute lung injury: From bedside to bench and back. Blood 2011, 117:1463-1471.
26. Loupy A., Hill G.S., Jordan S.C. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012, 8:348-357.
27. Taniguchi K., Taniguchi K., Yoshihara S., et al. Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors. Bone Marrow Transplant 2012, 47:1338-1342.
28. Schroeder M.A., DiPersio J.F. Mouse models of graft-versus-host disease: Advances and limitations. Dis Model Mech 2011, 4:318-333.
29. Yamazaki S., Ema H., Karlsson G., et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011, 147:1146-1158.
30. Li L., Bhatia R. Stem cell quiescence. Clin Cancer Res 2011, 17:4936-4941.
31. Harris A.C., Ferrara J.L.M., Levine J.E. Advances in predicting acute GVHD. Br J Haematol 2013, 160:288-302.
32. Chatenoud L., Bach J.F. Antigenic modulation: A major mechanism of antibody action. Immunol Today 1984, 5:20-25.
33. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001, 1:118-129.
34. Gerber H.P., Koehn F.E., Abraham R.T. The antibody-drug conjugate: An enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 2013, 30:625-639.
35. Zachary A.A., Kopchaliiska D., Jackson A.M., Leffell M.S. Immunogenetics and immunology in transplantation. Immunol Res 2010, 47:232-239.
36. Del Campo A.B., Carretero J., Aptsiauri N., Garrido F. Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 2012, 79:147-154.
37. Lippitz B.E. Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol 2013, 14:e218-e228.